Results 181 to 190 of about 4,346,534 (345)

Dynamic Changes in Metabolic Syndrome and Risk of Hepatocellular Carcinoma: Evidence From a Nationwide Japanese Cohort

open access: yesLiver International Communications, Volume 7, Issue 4, December 2026.
ABSTRACT Aim Metabolic syndrome (MetS) is a known risk factor for hepatocellular carcinoma (HCC), but the impact of cumulative MetS burden and changes in MetS status over time remains unclear. This study aimed to assess these associations using a large‐scale Japanese health dataset.
Yutaka Yata   +9 more
wiley   +1 more source

Chronic Hepatitis B in the United States: Current Landscape, Unmet Needs and Future Directions

open access: yesJournal of Viral Hepatitis, Volume 33, Issue 12, December 2026.
ABSTRACT Chronic hepatitis B (CHB) infection represents a major public health challenge in the US, with substantial unmet needs related to timely diagnosis, treatment, monitoring and disease management. This narrative review explores the CHB landscape in the US, including gaps in patient care, the evolving therapeutic landscape, the clinical utility of
Chari Cohen   +3 more
wiley   +1 more source

Pilot Evaluation of Simplified HBV DNA Extraction-LAMP Workflows for Hepatitis B Molecular Testing in Resource-Limited Settings. [PDF]

open access: yesDiagnostics (Basel)
Kham-Kjing N   +6 more
europepmc   +1 more source

Occult HBV Infection in Patients Infected by HIV or HCV: Comparison between HBV-DNA and Two Assays for HBsAg

open access: yes
We investigated the frequency and serological correlates of occult hepatitis B virus infection (OBI) and the potential impact of a highly sensitive assay for HBsAg in subjects infected by human immunodeficiency virus (HIV) or hepatitis C virus (HCV), who
Klizia Mizzoni   +9 more
core   +1 more source

Anti‐Viral Treatment Eligibility and Treatment Uptake Among People With Chronic Hepatitis B in Australia: The REACH‐B Study

open access: yesJournal of Viral Hepatitis, Volume 33, Issue 12, December 2026.
ABSTRACT Treatment indication for chronic hepatitis B (CHB) varies across clinical guidelines. This study evaluated treatment eligibility and uptake in a large Australian cohort of people with CHB. The REACH‐B study recruited people with CHB managed through a national network of healthcare services.
Behzad Hajarizadeh   +28 more
wiley   +1 more source

The Safety, Pharmacokinetics, and Antiviral Activity of ABI‐4334, A Novel Next‐Generation Hepatitis B Capsid Assembly Modulator

open access: yesJournal of Viral Hepatitis, Volume 33, Issue 12, December 2026.
ABSTRACT Novel, well‐tolerated, short‐term therapeutics for chronic hepatitis B virus infection (cHBV) are needed. ABI‐4334 is a next‐generation capsid assembly modulator that targets the HBV core protein. The safety, tolerability, and pharmacokinetics of ABI‐4334 in healthy volunteers and participants with cHBV and antiviral effects in participants ...
Edward J. Gane   +11 more
wiley   +1 more source

Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg‐negative chronic HBV infection

open access: yesAlimentary Pharmacology and Therapeutics, 2018
L. Kuhnhenn   +13 more
semanticscholar   +1 more source

APOBEC3B edits HBV DNA and inhibits HBV replication during reverse transcription

open access: yesAntiviral Research, 2018
Yan-Meng Chen   +10 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy